Compare Citius Pharmaceuticals Inc (CTXR) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Procter & Gamble Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Procter & Gamble Co trades at $145.25 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 18173.5× Citius Pharmaceuticals Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PG | |
|---|---|---|
Market Cap | $18.73M | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $167.18 |
52-Week Low | $0.48 | $138.10 |
Enterprise Value | $14.95M | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Procter & Gamble (PG) trades at $146.38, up 0.42% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.90. Revenue reached $84.28B in 2025, with a net income margin of 18.44% and robust cash flow from operations of $17.82B. Analyst consensus is bullish with a $161.20 price target, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
The outlook for PG is positive due to steady earnings growth and dividend reliability, but risks include premium valuation concerns and soft demand headwinds. Investors may find opportunity in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
